%20BIANCO.png)
Join Lever Bio in advancing promising research and driving innovative drug development in the immuno-oncology field
Our goal is to develop novel immune checkpoint inhibitory and stimulatory strategies to overcome resistance to current immunotherapies, paving the way for next-generation immunotherapies and innovative combination treatments.
To optimize the efficacy of immunotherapy combination strategies against solid tumors, we will implement a biomarker-driven approach for patient selection.
Lever Bio's pipeline consists of solid tumor microenvironment reprogramming agents and T-cell fitness potentiators
T lymphocyte
NK lymphocyte
Cancer-restraining fibroblasts (CAF)
M1 macrophage
Science
Cancer immunotherapy, including immune checkpoint inhibitors and adoptive cell therapies, has emerged as a potentially curative treatment for a subset of advanced cancers. However, most patients with solid tumors fail to derive clinical benefit from these therapies.
A key mechanism of resistance to cancer immunotherapy is the ability of the solid tumor microenvironment (TME) to drive a metabolically hostile and immunosuppressive phenotype
T lymphocyte
While cytotoxic T cells are historically the primary target of immunotherapy, the recruitment of immunosuppressive cell subpopulations within the TME, along with the upregulation of inhibitory checkpoints, limits effector T cell infiltration and function in solid tumors.
In this metabolically hostile TME, tumor-infiltrating T cells encounter increased acidity, hypoxia, oxidative stress, and dysregulated lipid metabolism.
Myeloid-derived suppressor cell (MDSC)
M2 macrophage
Treg lymphocyte
NK
lymphocyte
Cancer-associated fibroblasts (CAF)